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Abstract Latent transforming growth factor-L binding protein-
1 (LTBP-1), plays an important role in controlling localisation
and activation of transforming growth factor-L (TGF-L). We
show that alternative splicing generates a form of mRNA which
lacks bases 1277^1435 (termed LTBP-1v53). The 53 amino
acids encoded by these bases include the eighth cysteine of the
first cysteine repeat and a consensus heparin binding sequence.
Sequencing of genomic clones showed that alternative splicing
resulted from the use of an intra-exonic 3P splice acceptor site.
The loss of the heparin binding site implies that LTBP-1v53 will
bind to the extracellular matrix less efficiently than LTBP-1.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
There are numerous reports showing a role for TGF-L in a
wide variety of normal cellular processes, including cell
growth [1], cell di¡erentiation [2^4], matrix biosynthesis [5],
angiogenesis [6,7], bone formation [8,9] and embryonic devel-
opment [10]. TGF-L has been shown to play a role in wound
healing [11], ¢brosis [12] and immunosuppression [13,14], and
has also been implicated in atherosclerosis [15^17] and cancer
[18^20]. There are three mammalian isoforms of TGF-L
(TGF-L1 to TGF-L3) which are similar to each other
(s 70% amino acid homology) and highly conserved between
species. The TGF-L isoforms are exported by cells in various
latent complexes which lack any known biological activity. A
small latent complex (V100 kDa) consisting of the active
TGF-L homodimer (25 kDa) is non-covalently associated
with a disul¢de-bonded homodimer of a latency associated
peptide (LAP). LAP is the amino-terminal remnant of the
TGF-L precursor and is su⁄cient to confer latency. Large
latent TGF-L complexes are formed by the association of
the small latent complex with a latent TGF-L binding protein
(LTBP) to form a prototypical complex of 270 kDa. There are
four LTBP genes (LTBP-1 to -4) which have all been cloned.
LTBP-1 forms a large latent complex disul¢de bonding to
LAP [21,22]. Recently, an additional protein termed the latent
TGF-L complexed protein-1 (LTCP-1) was also found to bind
to the large latent TGF-L in CHO cell cultures [23].
Cell culture experiments suggest that LTBP-1 may play an
important role for some types of cells in the assembly and
rapid secretion of TGF-L1 [24] and have implicated LTBP-1
in the regulation of TGF-L activation [25,26]. Immunohisto-
chemical and immunoelectron microscopy studies have local-
ised LTBP to the extracellular matrix and it has also been
suggested that LTBP is a structural component of the matrix
[27^29].
LTBP-1 expressed in di¡erent cell types is heterogeneous in
size ranging from 125 kDa in platelets [30] to 190 kDa in
¢broblasts [31]. This heterogeneity may be accounted for, at
least in part, by the existence of alternatively spliced short
(LTBP-1S) and long (LTBP-1L) forms of LTBP-1 [32].
LTBP-1S has multiple EGF-like repeats, some of which con-
tain consensus calcium binding sites, three eight cysteine re-
peats of a novel type, an RGD motif and an eight amino acid
sequence homologous to the laminin B2 chain [31]. LTBP-1L
contains additional 346 N-terminal amino acids with one ad-
ditional EGF-like repeat [32].
LTBP-1 eight cysteine repeat regions are homologous to the
cysteine repeats in ¢brillin-1 which also contain eight cys-
teines. The NMR structure determined for one of the ¢brillin
cysteine repeats suggested that the eight cysteines form four
pairs of stabilising disul¢de bonds [33]. Mutations which re-
place cysteine residues in the cysteine repeats of ¢brillin-1
occur in Marfan’s syndrome [34^36]. Mutations in the EGF-
like domains may also lead to Marfan’s syndrome, possibly
because the loss of calcium binding sites increases the suscept-
ibility of ¢brillin-1 to proteolysis [34,37]. Calcium binding has
been shown to protect both ¢brillin-1 and LTBP-1 against
proteolysis [37,38].
Studies of truncated forms of LTBP-1S indicated that the
amino acids 294 to 441 are required for the binding of LTBP-
1 to the extracellular matrix [39]. LTBP-1L had a greater
a⁄nity for the extracellular matrix than LTBP-1S. Increased
or decreased amounts of LTBP-1 associated with the extra-
cellular matrix have been reported in various diseases, includ-
ing prostate cancer [40], human chronic pancreatitis [41], col-
orectal adenomas [42], ovarian neoplasms [43], rheumatoid
arthritis [44], muscular dystrophy [45], carcinoid heart disease
[46], and glomerulosclerosis [47]. These changes in LTBP-1
amounts may result from either changes in protein produc-
tion, protein stability or in the a⁄nity of the protein for the
extracellular matrix. Here we have examined whether there
are alternatively spliced forms of LTBP-1 with sequence dif-
ferences which might have a major e¡ect on the ability of
LTBP-1 to bind to the extracellular matrix.
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2. Materials and methods
2.1. Reverse transcription (RT)-PCR and PCR
Total RNA was extracted from normal human breast (HBR) cells
or rat tissues using RNeasy kit (Qiagen) according to the manufac-
turer’s instructions. One Wg of total RNA in 11 Wl of DEPC treated
water was denatured for 10 min at 65‡C and then chilled on ice. To
the denatured RNA was added 4 Wl of 5Uavian myelomavirus reverse
transcriptase (AMV-RT) bu¡er (Promega), 0.5 Wl (2 units) of AMV-
RT (Promega), 2 Wl of 2 mM dNTPs, 1 Wl of 100 mM dithiothreitol,
0.5 Wl of RNAsin (Promega) and 1 Wl of random hexamer primers
(Pharmacia). The samples were incubated at 42‡C for 2 h and placed
on ice to terminate the reaction. For PCR ampli¢cation, 5 Wl of
cDNA was mixed with 4 Wl of 10UTaq Polymerase bu¡er (Pharma-
cia), 5 Wl of 2 mM dNTPs, 2.5 Wl of each primer (10 pmoles), and 21
Wl of water and overlaid with 50 Wl of mineral oil. The reaction was
hot started by heating to 95‡C for 90 s then reducing the temperature
to 80‡C and adding 10 Wl, containing 1 Wl of 10UTaq Polymerase
bu¡er, 0.5 Wl of (2.5 units) Taq Polymerase (Pharmacia), and 8.5 Wl of
water. The thermal cycling pro¢le was 1 min at 95‡C, 1 min at 60‡C
followed by 90 s at 72‡C for 35 cycles. The PCR products were
separated by agarose gel electrophoresis and visualised with ethidium
bromide. Bands were puri¢ed using a gel extraction kit (Qiagen) and
cloned into pGem-T-Easy (Promega). DNA sequencing was per-
formed in ABI Prism automated DNA sequencer using the dye ter-
minator procedure. Plasmid DNA was ampli¢ed as described above
except that plasmid DNA was used in place of cDNA.
2.2. LR-PCR
Cosmid DNA was ampli¢ed using LA Taq PCR kit Ver. 2 (Ta-
kara). One Wl of cosmid DNA (500 ng/50 Wl), 1 Wl of each primer (10
pmoles), 8 Wl of dNTP (2.5 mM each) and 20 Wl of water was heated
to 97‡C for 90 s, cooled to 80‡C, and a start mixture containing 0.5 Wl
of LA Taq (2.5 units), 5 Wl of 10ULA PCR Bu¡er II (Mg2 plus), and
14.5 Wl of water, was added. The PCR parameters for long range
ampli¢cations were denaturation for 20 s at 98‡C, annealing and ex-
tension for 20 min at 68‡C for 14 cycles. For the following 16 cycles
the conditions were the same except that the extension time was in-
creased by 15 s each cycle.
2.3. Southern-blot analysis and library screening
DNA was prepared using a midi-prep kit (Qiagen). Following elec-
trophoresis, DNA was denatured and transferred to nylon membranes
(Hybond, Amersham) and u.v. cross-linked [48]. 32P-labeled probes
were made by random priming using an oligonucleotide labeling kit
(Pharmacia). The ¢lters were hybridised to the probe at 60‡C in
3USSC (1USSC contains 150 mM NaCl and 15 mM sodium citrate),
dextran sulfate (5%), 10UDenhardt’s solution (1UDenhardt’s solu-
tion contains 0.02% Ficoll 400, 0.02% polyvinylpyrrolidone and 0.02%
BSA), salmon sperm DNA (250 Wg/ml), and SDS (0.1%) overnight.
The ¢lters were rinsed once and washed twice at 60‡C for 30 min in
1USSC/0.1% SDS, and exposed overnight to a PhosphorImager
screen (Molecular Dynamics).
A human cosmid library for chromosome 2 (LL02NC02) obtained
from the UK HGMP Resource Centre on stamped ¢lters was
screened by hybridisation to a 32P-labeled probe as described above.
3. Results
RNA isolated from normal human breast epithelial cells in
culture was reverse transcribed using random hexamers then
ampli¢ed by PCR using primers A and B (Table 1). This
reaction produced two products, one of 951 bp, the expected
size for LTBP-1 and one 159 bp shorter (Figs. 1 and 2a). Both
products were isolated from the gel, cloned into pGEM-T-
Easy and sequenced. Comparison of the sequences with the
EMBL database showed that both products were fragments of
LTBP-1 cDNA but that the shorter fragment lacked 159 bp
corresponding to nucleotides 1277 to 1435. This deletion cor-
responds to loss of a 53 amino acid sequence (Fig. 2b). Ex-
amination of the coding sequence showed that the region
deleted in the LTBP-1 contained the eighth cysteine of the
¢rst cysteine repeat and a consensus heparin binding site
(1330^1357, Fig. 2c). We have de¢ned this short form of
LTBP-1, LTBP-1v53.
To con¢rm the existence of alternative spliced forms the
genomic structure of this region of LTBP-1 was de¢ned. A
cosmid library of chromosome 2 was screened using a probe
corresponding to nucleotides 1009^1959. Three cosmids
(AE25e19, AE68b4 and AE24g16) were subsequently isolated
and restriction mapping showed that they contained inserts of
approximately 42 kb, 15 kb and 12 kb, respectively. To de-
termine the intron-exon boundaries in the spliced region of
LTBP-1, cosmid AE25e19 was sequenced from primers A, C,
D, E, F, G and H (Table 1). The sequences showed that bases
989 to 1111, 1112 to 1276 and 1277 to 1504 form discrete
exons (Fig. 2b). LA-PCR analysis using primers A, C, D
and E generated fragments of approximately 10 kb and 4 kb,
corresponding to the introns separating exons A and B and B
and C, respectively.
Alignment of the cDNA sequences from the two spliced
forms of LTBP-1 with the genomic sequence showed that
159 bases absent in the short form of the gene did not exist
as a discrete exon but were the 5P part of exon C. This ob-
servation suggested that splicing was the result of alternative
use of two exons, one a duplicate of 69 bases at the 3P end of
exon C or that exon C contained an internal splice junction.
Sequence analysis showed that exon C contained a complete
internal splice acceptor site corresponding to bases 1404 to
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Table 1
Primer sequences
Primer Sequence
A CAAGGTGTATGCCCTAATGGTGAGTGTTTG
B CTCACTGGCCATAAATCCTGCTGGGCAAATG
C GGGAGAGGTGGAGGATGAGTACTTTTAG
D GCCCACACTACAACAGCAGAGCTGCTTG
E CAGTGTATGTACCCTCTGTCTGTTCACCT
F GAAGGTCAGGGCCTCCACTGGCTCTTC
G CGCAGGCCAATCCATCACCATGTAGGTAAAG
H GGTAGGATCCGGCCCAAATCCTATTTTG
I GGAAACTGTGGATGCAGATGAATAG
Fig. 1. Identi¢cation of two PCR products of LTBP-1 cDNA from
human breast epithelial cells. Lane 1: Bands of 951 bp and 792 bp
ampli¢ed using primers A and B (Table 1).
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1435 of the LTBP-1 cDNA, the use of which would generate
LTBP-1v53 (Fig. 2c, Fig. 3). LR-PCR using primers F and G
with genomic DNA isolated from human lymphocytes gener-
ated a single product (132 bp), supporting the suggestion that
the 3P end of exon C has not been duplicated elsewhere in the
gene and that two isoforms are generated by the use of alter-
native 3P splice acceptor sites.
To determine any tissue speci¢c variation in the splicing
pattern and the approximate amounts of the two spliced
forms, RNA was isolated from a series of rat tissues and
reverse transcribed from random hexamers. LTBP-1 cDNA
was ampli¢ed using primers A and I, the products were sep-
arated on a 1% agarose gel and Southern blotted. The prod-
ucts were hybridised to an LTBP-1 cDNA probe, washed and
visualised by phosphorimaging. Most tissues expressed both
forms of the LTBP-1 cDNA (Fig. 4). However, in the spleen
only LTBP-1 and not LTBP-1v53 was detected. These data
suggest that in most tissues there is competition between the
two splice acceptor sites but that other tissue speci¢c factors
are used to express a preferred form in a subset of tissues.
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Fig. 2. LTBP-1. a: Structure of LTBP-1 protein showing the region encoded by the sequence ampli¢ed as in Fig. 1 marked by arrows.
b: Three exons of LTBP-1: exon C undergoes alternative splicing with loss of a region encoding a putative heparin binding domain and the
eighth cysteine of a cysteine repeat. c: DNA and amino acid sequence of the alternatively spliced region. The vertical arrow indicates the intra-
exonic splice site. The cysteine residue encoded by exon C is italicised: the putative heparin binding domain is boxed. Both are deleted in the
alternative LTBP-1v53 form. Numbers refer to the DNA sequence of Kanzaki et al. [31].
Fig. 3. Intron/exon boundaries of exons A, B and C.
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4. Discussion
The data presented show that human and rat LTBP-1 can
be alternatively spliced to give a new, shorter form de¢ned
here as LTBP-1v53 and that most normal rat tissues produce
both of the splice variants. Furthermore, PCR analysis and
sequencing of a cosmid containing a portion of the human
LTBP-1 gene showed that the di¡erent spliced variants of
LTBP-1 did not arise by splicing out an exon or alternative
use of two similar exons, one with a 5P or 3P extension. The
sequence showed that the di¡erences arose from alternative
use of two competing 3P splice junctions. This form of splicing
frequently occurs where there are two possible (C/T)AG close
together as has been found for the porcine and rat pro-opio-
melanocortin [49] and for an adipocyte serine protease [50].
However, for LTBP-1 there are two complete splice acceptor
sites, one 159 bp downstream from the other and contained
completely within the coding region of the long form of the
exon. This type of splicing has been previously observed in
¢bronectin in which an exon contains a splice junction which
can be used to generate a shorter form of the mRNA [51,52].
A recent abstract has described RT-PCR products from rat
hepatocyte LTBP-1 which di¡ered by 159 bp and may corre-
spond to the alternatively spliced forms de¢ned here, but the
deleted sequence was not reported [53]. The relationship be-
tween the new alternatively spliced forms of LTBP-1 and the
previously described LTBP-1S and LTBP-1L forms also re-
mains to be de¢ned.
The sequence deleted in LTBP-1v53 codes for 53 amino
acids which do not include any consensus binding sites for
calcium. Decreased resistance to proteolysis of the LTBP-
1v53 form by the loss of calcium binding sites is therefore
unlikely. However, the sequence deleted in LTBP-1v53 in-
cludes the eighth cysteine of the ¢rst of three cysteine repeats.
These cysteine repeats are a protein motif which LTBP-1
shares with the other LTBP family members and with ¢brillin.
The ¢rst cysteine repeat in LTBP-1 is coded in two exons with
seven of the eight cysteines in one exon and the eighth, C-
terminal cysteine, encoded by the adjacent exon. This genomic
structure is similar to that of the cysteine repeats in LTBP-2
[54] and in ¢brillin in which four out of six repeats are en-
coded within two exons [55].
Structural studies of an isolated cysteine repeat from ¢bril-
lin have shown that the eight cysteines form four disul¢de
bonds, with the eighth cysteine bonded to the ¢fth cysteine.
In Marfan’s syndrome mutations have been detected in 19
distinct cysteine residues in ¢brillin-1 [34]. Two of these mu-
tations involve loss of the eighth cysteine of a repeat, one
arising from a point mutation [36], the other resulting from
exon skipping [56,57]. In LTBP-1v53 there is no neighbouring
cysteine to replace the residue deleted by alternative splicing
and it is therefore likely that the structure of this region of the
protein will be altered.
A consensus heparin binding site (1330^1357) is also deleted
in LTBP-1v53. Deletion mapping has shown that some or all
of residues 294 to 441, which contain the consensus heparin
binding site, are required for the binding of LTBP-1 to the
extracellular matrix. Heparin binding sites are present in sev-
eral growth factors and regulatory molecules (e.g. vascular
endothelial growth factor (VEGF) and platelet derived growth
factor (PDGF)) and have been implicated in localising these
molecules to the extracellular matrix. It may be noted that
alternative splicing of VEGF mRNA also generates proteins
with (VEGF189) or without (VEGF121, VEGF165) heparin
binding sites and the form of VEGF without a heparin bind-
ing site does not bind e⁄ciently to the extracellular matrix
[58]. The consensus heparin binding site in LTBP-1 may there-
fore serve the same role and it is plausible that LTBP-1v53,
which lacks the consensus heparin binding site, will have a
di¡erent pro¢le of interactions with the extracellular matrix
from LTBP-1. It remains to be determined whether expression
of LTBP-1v53 is correlated with disease.
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